Please assess the completion status of the following clinical trial:

Trial Title: Determination of Safe and Effective Dose of Romiplostim (AMG 531) in Subjects With Myelodysplastic Syndrome (MDS)Receiving Hypomethylating Agents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria: - Diagnosis of MDS by bone marrow biopsy based on the World Health Organization (WHO) classification - Low, Intermediate-1 or Intermediate-2 risk category MDS using the IPSS (International Prognostic Scoring System) - Planned to receive either azacytidine 75 mg/m2 by subcutaneous administration each day for 7 days or decitabine 20 mg/m2 by intravenous administration each day for 5 days for at least 4 cycles Exclusion Criteria:~* Prior exposure to \>3 cycles hypomethylating agents~* Prior history of leukemia or aplastic anemia~* Prior history of bone marrow transplantation~* Prior malignancy (other than in situ cervical cancer or basal cell cancer of the skin) unless treated with curative intent and without evidence of disease for ³ 3 years before randomization~* Active or uncontrolled infections~* Unstable angina, congestive heart failure \[NYHA (New York Heart Association) \> class II\], uncontrolled hypertension \[diastolic \> 100 mmHg\], uncontrolled cardiac arrhythmia, or recent (within 1 year) myocardial infarction~* History of arterial thrombosis ( eg, stroke or transient ischemic attack) in the past year~* History of venous thrombosis that currently requires anti-coagulation therapy~* Received IL-11 within 4 weeks of screening~* Less than 4 weeks since receipt of any therapeutic drug or device that is not FDA approved for any indication~* Have previously received any other thrombopoietic growth factor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose level 1 500 AMG 531 (Part A - azacitidine) (Type: ACTIVE_COMPARATOR): 500 mcg AMG 531 weekly via subcutaneous injection + 75 mg/m2 azacitidine for 4 cycles
- Dose level 1 750 AMG 531 (Part B - decitabine) (Type: ACTIVE_COMPARATOR): 750 mcg AMG 531 weekly via subcutaneous injection + 20 mg/m2 decitabine for 4 cycles
- Dose level 2 750 AMG 531 (Part A - azacitidine) (Type: ACTIVE_COMPARATOR): 750 mcg AMG 531 weekly via subcutaneous injection + 75 mg/m2 azacitidine for 4 cycles
- Placebo (Part A - azacitidine) (Type: PLACEBO_COMPARATOR): Placebo weekly via subcutaneous injection + 75 mg/m2 azacitidine for 4 cycles
- Placebo (Part B - decitabine) (Type: PLACEBO_COMPARATOR): Placebo weekly via subcutaneous injection + 20 mg/m2 decitabine for 4 cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).